论文部分内容阅读
目的观察应用康柏西普注射液玻璃体腔注射治疗眼内新生血管性疾病对眼压变化的影响。方法前瞻性、开放性研究。经最佳矫正视力(BCVA)、眼压、眼底彩色照相,光学相干断层扫描(OCT)及荧光素眼底血管造影(FFA+ICGA)检查确诊的眼内新生血管性疾病患者60例,60只眼纳入研究。所有患眼均行10mg/ml的康柏西普注射液0.05ml(含康柏西普0.5mg)玻璃体腔注射。观察术前及术后眼压变化情况。结果行玻璃体腔注射术后有26例眼压升高,约占43.33%。术后5min、30min眼压较术前不同程度的升高,差异具有统计学意义(t=-5.28、-4.44,P<0.05),治疗后1h、1d、2周后眼压较术前相比差异无统计学意义(t=-1.36、-0.26、1.23,P=0.18、0.80、0.23)。结论玻璃体腔注射康柏西普治疗新生血管性眼病术后早期可引起不同的程度的眼压升高。
Objective To observe the effect of intraocular neovascular disease (IOP) on intraocular pressure (IOP) by intraocular injection of Compaqeep injection. Methods Prospective, open-label study. 60 patients with intraocular neovascular disease diagnosed by BCVA, intraocular pressure, fundus color photography, optical coherence tomography (OCT) and fluorescein angiography (FFA + ICGA), 60 eyes Included in the study. All affected eyes were treated with intravitreal injection of concomitant prednisone (0.05ml) containing 10mg / ml of aspirin 0.5mg. Observation of preoperative and postoperative changes in intraocular pressure. Results Intraocular pressure increased after intravitreal injection of 26 cases, accounting for 43.33%. The intraocular pressure at 5 min and 30 min after operation was significantly higher than that before operation (t = -5.28, -4.44, P <0.05). The intraocular pressure at 1, The difference was not statistically significant (t = -1.36, -0.26, 1.23, P = 0.18, 0.80, 0.23). Conclusion Intravitreal injection of compstatin can induce different degrees of intraocular pressure elevation in the early postoperative period of neovascular ophthalmopathy.